December 19, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Acasti Pharma Inc.
Registration Statement on FormF-1
FileNo. 333-220755
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acasti Pharma Inc., a Québec corporation (the “Company”) respectfully requests that the Securities and Exchange Commission (the “Commission) accelerate the effective date of the above-referenced Registration Statement (the “Registration Statement”) so that the same will become effective at 4:30 p.m. on December 19, 2017 or as soon thereafter as is practicable.
The Company also requests the Commission confirm the effective date and time of the Registration Statement to Company counsel, Osler, Hoskin & Harcourt LLP, Attention: Jason Comerford, by email toJComerford@osler.com.
| ACASTI PHARMA INC. | ||
| By: | /s/ Janelle D’Alvise | |
| Name: | Janelle D’Alvise | |
| Title: | Chief Executive Officer | |